Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer

Journal of Sexual Medicine

Volumn 11, Issue 8, 2014, Pages 2100-2108

  Plym, Anna ^a   Folkvaljon, Yasin ^b   Garmo, Hans ^b,c   Holmberg, Lars ^b,c   Johansson, Eva ^b   Fransson, Per ^d   Stattin, Pär ^d   Lambe, Mats ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Drug prescriptions; Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Prostate cancer; Radical prostatectomy; Radiotherapy; Sweden

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; EDUCATIONAL STATUS; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; INCOME; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SOCIAL STATUS; VERY ELDERLY; WATCHFUL WAITING;

DRUG PRESCRIPTIONS; ERECTILE DYSFUNCTION; PHOSPHODIESTERASE TYPE 5 INHIBITORS; PROSTATE CANCER; RADICAL PROSTATECTOMY; RADIOTHERAPY; SWEDEN;

ADULT; AGED; CASE-CONTROL STUDIES; DRUG PRESCRIPTIONS; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SWEDEN;

EID: 84904902259     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12586     Document Type: Article

References (29)

1. Incrocci L. Sexual function after external-beam radiotherapy for prostate cancer: What do we know? Crit Rev Oncol Hematol 2006;57:165-173.
2. Matthew AG, Goldman A, Trachtenberg J, Robinson J, Horsburgh S, Currie K, Ritvo P. Sexual dysfunction after radical prostatectomy: Prevalence, treatments, restricted use of treatments and distress. J Urol 2005;174:2105-2110.
3. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, Holmberg L. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-796.
4. Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 2002;94:862-871.
5. Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL. General quality of life 2 years following treatment for prostate cancer: What influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 2003;21:1147-1154.
6. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J Sex Med 2011;8:560-566.
7. Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM, McLaughlin PW, Sanda MG. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: Potential influence of sexual motivation and/or indifference. Urology 2006;68:166-171.
8. Perez MA, Meyerowitz BE, Lieskovsky G, Skinner DG, Reynolds B, Skinner EC. Quality of life and sexuality following radical prostatectomy in patients with prostate cancer who use or do not use erectile aids. Urology 1997;50:740-746.
9. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306:1205-1214.
10. Bergman J, Gore JL, Penson DF, Kwan L, Litwin MS. Erectile aid use by men treated for localized prostate cancer. J Urol 2009;182:649-654.
11. Kyrdalen AE, Dahl AA, Hernes E, Smastuen MC, Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221-232.
12. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002;95:2397-2407.
13. Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, Hoffman RM, Potosky AL. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: Patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol 2005;174:646-650, discussion 50.
14. Prasad MM, Prasad SM, Hevelone ND, Gu X, Weinberg AC, Lipsitz SR, Palapattu GS, Hu JC. Utilization of pharmacotherapy for erectile dysfunction following treatment for prostate cancer. J Sex Med 2010;7:1062-1073.
15. Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, Widmark A, Lambe M, Adolfsson J, Varenhorst E, Johansson JE, Stattin P, for N, Sweden PC. Cohort profile: The national prostate cancer register of Sweden and prostate cancer data base Sweden 2.0. Int J Epidemiol 2012;42:956-967.
16. The National Prostate Cancer Register of Sweden. Annual report 2011. Available at: http://www.npcr.se/rapporter (accessed December 10, 2013).
17. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M. The new Swedish Prescribed Drug Register-Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-735.
18. National Comprehensive Cancer Network Web Site. NCCN clinical practice guidelines in oncology. Prostate cancer: National Comprehensive Cancer Network. Version 1.2010. 2009. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed December 10, 2013).
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
20. The Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV), Sweden. Decisions on reimbursed medicines. 2013. Available at: http://www.tlv.se/beslut/sok/beslut-lakemedel/ (accessed December 10, 2013).
21. Travison TG, Hall SA, Fisher WA, Araujo AB, Rosen RC, McKinlay JB, Sand MS. Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys. J Sex Med 2011;8:3051-3057.
22. Nordin M, Dackehag M, Gerdtham UG. Socioeconomic inequalities in drug utilization for Sweden: Evidence from linked survey and register data. Soc Sci Med 2013;77:106-117.
23. DeLamater JD, Sill M. Sexual desire in later life. J Sex Res 2005;42:138-149.
24. Kimura M, Caso JR, Banez LL, Koontz BF, Gerber L, Senocak C, Donatucci CF, Vujaskovic Z, Moul JW, Polascik TJ. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int 2012;110:E931-938.
25. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436-445.
26. Lee DJ, Cheetham P, Badani KK. Penile rehabilitation protocol after robot-assisted radical prostatectomy: Assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency. BJU Int 2010;105:382-388.
27. Salonia A, Gallina A, Zanni G, Briganti A, Deho F, Sacca A, Suardi N, Barbieri L, Guazzoni G, Rigatti P, Montorsi F. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008;53:564-570.
28. Carvalheira AA, Pereira NM, Maroco J, Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: A study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med 2012;9:2361-2369.
29. Gruenwald I, Shenfeld O, Chen J, Raviv G, Richter S, Cohen A, Vardi Y. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006;50:134-140.